Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 86 | 2024 | 5709 | 6.880 |
Why?
|
Cancer Vaccines | 21 | 2024 | 1051 | 4.450 |
Why?
|
Antigens, Neoplasm | 20 | 2024 | 1993 | 3.640 |
Why?
|
Immunotherapy | 35 | 2024 | 4652 | 2.970 |
Why?
|
Skin Neoplasms | 37 | 2024 | 5821 | 2.380 |
Why?
|
Neoplasms | 34 | 2024 | 22170 | 1.540 |
Why?
|
Antibodies, Monoclonal | 30 | 2024 | 9177 | 1.480 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2024 | 11742 | 1.290 |
Why?
|
Proto-Oncogene Proteins B-raf | 14 | 2023 | 2057 | 1.170 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 6 | 2022 | 1092 | 1.160 |
Why?
|
Immunologic Memory | 7 | 2021 | 1359 | 0.830 |
Why?
|
Uveal Neoplasms | 6 | 2020 | 341 | 0.810 |
Why?
|
Angiopoietin-2 | 1 | 2021 | 172 | 0.720 |
Why?
|
Antineoplastic Agents | 20 | 2020 | 13639 | 0.710 |
Why?
|
T-Lymphocytes | 17 | 2024 | 10194 | 0.710 |
Why?
|
Neoplasms, Second Primary | 3 | 2022 | 1052 | 0.690 |
Why?
|
Anus Neoplasms | 3 | 2022 | 329 | 0.690 |
Why?
|
Vulvar Neoplasms | 1 | 2022 | 263 | 0.660 |
Why?
|
Immunoconjugates | 2 | 2019 | 954 | 0.650 |
Why?
|
Intraoperative Care | 2 | 2013 | 767 | 0.640 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2022 | 4026 | 0.630 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2019 | 423 | 0.620 |
Why?
|
Immunotherapy, Adoptive | 4 | 2023 | 1469 | 0.610 |
Why?
|
MAP Kinase Kinase Kinases | 3 | 2016 | 255 | 0.600 |
Why?
|
Endometrial Neoplasms | 2 | 2017 | 1366 | 0.590 |
Why?
|
Sarcoma | 3 | 2013 | 1801 | 0.570 |
Why?
|
Polyethylene Glycols | 4 | 2018 | 1189 | 0.570 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 4 | 2023 | 641 | 0.560 |
Why?
|
Humans | 170 | 2024 | 761504 | 0.550 |
Why?
|
Radiotherapy | 3 | 2018 | 1499 | 0.540 |
Why?
|
Colitis | 5 | 2020 | 1233 | 0.540 |
Why?
|
Dendritic Cells | 3 | 2019 | 2747 | 0.540 |
Why?
|
Protein Kinase Inhibitors | 8 | 2023 | 5671 | 0.530 |
Why?
|
Oncolytic Viruses | 2 | 2020 | 344 | 0.520 |
Why?
|
Viral Vaccines | 1 | 2021 | 596 | 0.510 |
Why?
|
Epitopes | 3 | 2021 | 2503 | 0.510 |
Why?
|
Creatinine | 3 | 2024 | 1899 | 0.490 |
Why?
|
Aged, 80 and over | 47 | 2024 | 58976 | 0.490 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2020 | 9280 | 0.490 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2020 | 1784 | 0.480 |
Why?
|
Esophagogastric Junction | 4 | 2021 | 347 | 0.470 |
Why?
|
Mutation | 16 | 2024 | 30052 | 0.470 |
Why?
|
CD8-Positive T-Lymphocytes | 8 | 2023 | 4580 | 0.450 |
Why?
|
Immunity, Cellular | 4 | 2019 | 1560 | 0.450 |
Why?
|
Mucous Membrane | 5 | 2021 | 659 | 0.450 |
Why?
|
Middle Aged | 83 | 2024 | 220895 | 0.440 |
Why?
|
Cytokines | 8 | 2021 | 7396 | 0.440 |
Why?
|
Neoplasm Staging | 20 | 2024 | 11121 | 0.440 |
Why?
|
Aged | 77 | 2024 | 169289 | 0.440 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2016 | 891 | 0.430 |
Why?
|
Neoplasm Metastasis | 12 | 2020 | 4915 | 0.430 |
Why?
|
Lung Neoplasms | 9 | 2024 | 13380 | 0.420 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2022 | 4369 | 0.410 |
Why?
|
Immune System | 2 | 2023 | 796 | 0.400 |
Why?
|
Hydrolases | 1 | 2012 | 147 | 0.390 |
Why?
|
RNA | 1 | 2021 | 2726 | 0.380 |
Why?
|
Gamma Rays | 1 | 2013 | 318 | 0.380 |
Why?
|
Brain Neoplasms | 8 | 2022 | 9031 | 0.370 |
Why?
|
Kaplan-Meier Estimate | 13 | 2020 | 6484 | 0.370 |
Why?
|
Herpesvirus 1, Human | 1 | 2016 | 753 | 0.360 |
Why?
|
Female | 88 | 2024 | 392644 | 0.350 |
Why?
|
Islets of Langerhans | 3 | 2005 | 1341 | 0.350 |
Why?
|
Male | 86 | 2024 | 360804 | 0.350 |
Why?
|
Oncolytic Virotherapy | 1 | 2016 | 516 | 0.350 |
Why?
|
Adult | 73 | 2024 | 221177 | 0.350 |
Why?
|
Dacarbazine | 2 | 2012 | 559 | 0.350 |
Why?
|
Benzenesulfonates | 1 | 2010 | 166 | 0.350 |
Why?
|
Epothilones | 1 | 2010 | 42 | 0.350 |
Why?
|
Combined Modality Therapy | 9 | 2021 | 8529 | 0.340 |
Why?
|
Diabetes Mellitus, Type 1 | 7 | 2005 | 3415 | 0.340 |
Why?
|
Glutamate Decarboxylase | 3 | 2005 | 239 | 0.330 |
Why?
|
Tubulin Modulators | 1 | 2010 | 107 | 0.330 |
Why?
|
Molecular Targeted Therapy | 8 | 2019 | 2811 | 0.330 |
Why?
|
Esophageal Neoplasms | 4 | 2021 | 1654 | 0.330 |
Why?
|
Colonoscopy | 1 | 2017 | 1394 | 0.320 |
Why?
|
Proinsulin | 2 | 2005 | 135 | 0.290 |
Why?
|
Receptors, Interferon | 1 | 2007 | 116 | 0.280 |
Why?
|
Disease-Free Survival | 8 | 2017 | 6814 | 0.280 |
Why?
|
Antigen-Presenting Cells | 3 | 2022 | 964 | 0.270 |
Why?
|
Immunity, Innate | 1 | 2019 | 3065 | 0.270 |
Why?
|
Poly I-C | 2 | 2019 | 112 | 0.270 |
Why?
|
Tumor Escape | 2 | 2020 | 370 | 0.270 |
Why?
|
RNA, Messenger | 1 | 2021 | 12795 | 0.260 |
Why?
|
Survival Rate | 14 | 2021 | 12725 | 0.260 |
Why?
|
Isoenzymes | 3 | 2005 | 1687 | 0.260 |
Why?
|
Treatment Outcome | 24 | 2021 | 64680 | 0.250 |
Why?
|
Carcinoma | 1 | 2017 | 2330 | 0.250 |
Why?
|
Stomach Neoplasms | 3 | 2021 | 1459 | 0.250 |
Why?
|
Receptors, Antigen, T-Cell | 5 | 2023 | 2547 | 0.240 |
Why?
|
Adjuvants, Immunologic | 3 | 2020 | 1036 | 0.230 |
Why?
|
MAP Kinase Kinase 2 | 2 | 2014 | 92 | 0.220 |
Why?
|
Thalidomide | 1 | 2009 | 885 | 0.220 |
Why?
|
MAP Kinase Kinase 1 | 3 | 2014 | 332 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2021 | 10766 | 0.220 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5315 | 0.220 |
Why?
|
Head and Neck Neoplasms | 4 | 2024 | 2895 | 0.220 |
Why?
|
Kidney Transplantation | 3 | 2024 | 4234 | 0.210 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 4853 | 0.210 |
Why?
|
Maximum Tolerated Dose | 2 | 2017 | 883 | 0.210 |
Why?
|
Fatigue | 4 | 2020 | 1552 | 0.200 |
Why?
|
MAP Kinase Signaling System | 3 | 2014 | 1486 | 0.200 |
Why?
|
Autoimmunity | 3 | 2021 | 1356 | 0.200 |
Why?
|
Interleukin-10 | 2 | 2018 | 1175 | 0.200 |
Why?
|
Oleic Acids | 2 | 2019 | 74 | 0.200 |
Why?
|
Diabetes Complications | 1 | 2009 | 1315 | 0.200 |
Why?
|
Prognosis | 16 | 2021 | 29625 | 0.190 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 12463 | 0.190 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2021 | 1349 | 0.190 |
Why?
|
Mannitol | 2 | 2019 | 180 | 0.190 |
Why?
|
Th1 Cells | 3 | 2005 | 1036 | 0.190 |
Why?
|
Surgical Procedures, Operative | 1 | 2013 | 1922 | 0.190 |
Why?
|
Drug Synergism | 2 | 2017 | 1755 | 0.190 |
Why?
|
Retrospective Studies | 27 | 2024 | 80636 | 0.190 |
Why?
|
Vitamin D-Binding Protein | 2 | 1999 | 131 | 0.180 |
Why?
|
Drug Stability | 1 | 2021 | 291 | 0.180 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 3810 | 0.180 |
Why?
|
Peptides | 3 | 2021 | 4358 | 0.180 |
Why?
|
Interferon-gamma | 7 | 2018 | 3162 | 0.180 |
Why?
|
Ursodeoxycholic Acid | 1 | 2020 | 81 | 0.180 |
Why?
|
Indoles | 3 | 2013 | 1833 | 0.180 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2024 | 664 | 0.180 |
Why?
|
Medical Oncology | 3 | 2024 | 2321 | 0.170 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2019 | 38 | 0.170 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2020 | 108 | 0.170 |
Why?
|
Kidney Neoplasms | 4 | 2024 | 4249 | 0.170 |
Why?
|
Antigens, Viral | 1 | 2004 | 988 | 0.170 |
Why?
|
Atmosphere | 1 | 2019 | 32 | 0.170 |
Why?
|
Dextropropoxyphene | 2 | 1997 | 26 | 0.170 |
Why?
|
Th2 Cells | 1 | 2005 | 1060 | 0.170 |
Why?
|
Textiles | 1 | 2019 | 45 | 0.170 |
Why?
|
Budesonide | 1 | 2020 | 157 | 0.170 |
Why?
|
Polylysine | 1 | 2019 | 131 | 0.170 |
Why?
|
Immunologic Factors | 2 | 2021 | 1589 | 0.170 |
Why?
|
Animals | 17 | 2024 | 168459 | 0.160 |
Why?
|
Colitis, Microscopic | 1 | 2020 | 72 | 0.160 |
Why?
|
Portraits as Topic | 1 | 2019 | 32 | 0.160 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2005 | 1119 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 2 | 2021 | 1880 | 0.160 |
Why?
|
RNA Stability | 1 | 2021 | 329 | 0.160 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 8002 | 0.160 |
Why?
|
Sulfonamides | 3 | 2013 | 1978 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2017 | 5305 | 0.160 |
Why?
|
Pyridines | 1 | 2010 | 2875 | 0.160 |
Why?
|
Polymerization | 1 | 2019 | 158 | 0.160 |
Why?
|
Blood Cells | 1 | 2020 | 305 | 0.160 |
Why?
|
Follow-Up Studies | 13 | 2021 | 39106 | 0.160 |
Why?
|
Retreatment | 2 | 2017 | 598 | 0.160 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2018 | 85 | 0.160 |
Why?
|
Carcinoid Tumor | 1 | 2020 | 224 | 0.150 |
Why?
|
Interleukin-15 | 1 | 2018 | 185 | 0.150 |
Why?
|
Survival Analysis | 4 | 2019 | 10090 | 0.150 |
Why?
|
Interleukin-2 | 3 | 2018 | 1889 | 0.150 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3595 | 0.140 |
Why?
|
Morphine Derivatives | 1 | 1997 | 42 | 0.140 |
Why?
|
Interleukin-4 | 5 | 2016 | 1149 | 0.140 |
Why?
|
Apoptosis | 2 | 2013 | 9486 | 0.140 |
Why?
|
Alkaline Phosphatase | 1 | 2020 | 864 | 0.140 |
Why?
|
Substrate Specificity | 1 | 2021 | 1791 | 0.140 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 16981 | 0.140 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2014 | 3080 | 0.140 |
Why?
|
Adenocarcinoma | 3 | 2019 | 6346 | 0.140 |
Why?
|
Autoantigens | 4 | 2005 | 891 | 0.140 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 800 | 0.140 |
Why?
|
Remission, Spontaneous | 1 | 2017 | 384 | 0.140 |
Why?
|
Obesity | 1 | 2019 | 12947 | 0.140 |
Why?
|
Anorexia | 1 | 2017 | 154 | 0.140 |
Why?
|
Autoimmune Diseases | 2 | 2021 | 2244 | 0.130 |
Why?
|
Multiple Trauma | 1 | 1999 | 369 | 0.130 |
Why?
|
Membrane Proteins | 5 | 2019 | 7856 | 0.130 |
Why?
|
Lymphopenia | 1 | 2018 | 281 | 0.130 |
Why?
|
Toll-Like Receptors | 1 | 2020 | 589 | 0.130 |
Why?
|
Hypoglycemic Agents | 1 | 2009 | 3085 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 4 | 2017 | 20570 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 424 | 0.130 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3877 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 350 | 0.130 |
Why?
|
Disease Progression | 7 | 2020 | 13506 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2024 | 3514 | 0.130 |
Why?
|
Endocrine System Diseases | 1 | 2018 | 249 | 0.130 |
Why?
|
Immunity, Humoral | 1 | 2019 | 606 | 0.120 |
Why?
|
Membrane Glycoproteins | 2 | 2019 | 3702 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3734 | 0.120 |
Why?
|
Nephritis, Interstitial | 1 | 2016 | 155 | 0.120 |
Why?
|
Carbon Dioxide | 1 | 2019 | 1147 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 561 | 0.120 |
Why?
|
Thrombotic Microangiopathies | 1 | 2016 | 123 | 0.120 |
Why?
|
Radiosurgery | 3 | 2020 | 1342 | 0.120 |
Why?
|
History, 21st Century | 1 | 2021 | 1567 | 0.120 |
Why?
|
Cranial Irradiation | 2 | 2017 | 390 | 0.120 |
Why?
|
Anal Canal | 1 | 2017 | 373 | 0.120 |
Why?
|
Thyroid Diseases | 1 | 2017 | 386 | 0.120 |
Why?
|
Pyrimidinones | 2 | 2016 | 385 | 0.110 |
Why?
|
Diarrhea | 2 | 2020 | 1318 | 0.110 |
Why?
|
Vaccines | 1 | 2022 | 844 | 0.110 |
Why?
|
Pituitary Diseases | 1 | 2014 | 135 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 641 | 0.110 |
Why?
|
Quality of Health Care | 1 | 2009 | 4330 | 0.110 |
Why?
|
Pruritus | 1 | 2017 | 380 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Postoperative Complications | 2 | 2013 | 15631 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 3 | 2017 | 3164 | 0.110 |
Why?
|
Microsatellite Instability | 1 | 2017 | 716 | 0.110 |
Why?
|
Exanthema | 2 | 2016 | 503 | 0.110 |
Why?
|
Standard of Care | 1 | 2017 | 551 | 0.110 |
Why?
|
Genetic Engineering | 1 | 2019 | 933 | 0.110 |
Why?
|
Immediate-Early Proteins | 1 | 2016 | 449 | 0.110 |
Why?
|
Lymphocyte Activation | 3 | 2018 | 5486 | 0.110 |
Why?
|
Vaccination | 3 | 2021 | 3384 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 903 | 0.110 |
Why?
|
Young Adult | 10 | 2021 | 59243 | 0.110 |
Why?
|
Butadienes | 1 | 2013 | 107 | 0.110 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2017 | 1435 | 0.110 |
Why?
|
Leiomyosarcoma | 1 | 2017 | 422 | 0.110 |
Why?
|
Immunoenzyme Techniques | 3 | 2012 | 1705 | 0.100 |
Why?
|
Thionucleotides | 1 | 2012 | 112 | 0.100 |
Why?
|
Morphine | 1 | 1997 | 657 | 0.100 |
Why?
|
Mice | 8 | 2024 | 81525 | 0.100 |
Why?
|
Urologic Neoplasms | 1 | 2016 | 314 | 0.100 |
Why?
|
Protein Tyrosine Phosphatases | 2 | 2005 | 457 | 0.100 |
Why?
|
Fever | 2 | 2017 | 1618 | 0.100 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2200 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.100 |
Why?
|
Imidazoles | 2 | 2016 | 1180 | 0.100 |
Why?
|
Leg | 1 | 2017 | 1088 | 0.100 |
Why?
|
Feedback, Physiological | 1 | 2014 | 476 | 0.100 |
Why?
|
Tumor Burden | 4 | 2020 | 1893 | 0.100 |
Why?
|
Models, Immunological | 1 | 2014 | 513 | 0.100 |
Why?
|
Biopsy | 3 | 2020 | 6766 | 0.090 |
Why?
|
Pyridones | 2 | 2016 | 809 | 0.090 |
Why?
|
Pneumonia | 3 | 2021 | 2143 | 0.090 |
Why?
|
Peptide Fragments | 5 | 2015 | 5112 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1115 | 0.090 |
Why?
|
Hutchinson's Melanotic Freckle | 1 | 2011 | 25 | 0.090 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2013 | 882 | 0.090 |
Why?
|
Signal Transduction | 2 | 2011 | 23445 | 0.090 |
Why?
|
Amino Acid Sequence | 2 | 2017 | 13446 | 0.090 |
Why?
|
Organs at Risk | 1 | 2013 | 359 | 0.090 |
Why?
|
Cohort Studies | 8 | 2022 | 41487 | 0.090 |
Why?
|
Acetaminophen | 2 | 1995 | 554 | 0.090 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2014 | 828 | 0.090 |
Why?
|
Alopecia | 1 | 2014 | 412 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1935 | 0.090 |
Why?
|
Phenotype | 4 | 2022 | 16591 | 0.090 |
Why?
|
Influenza, Human | 1 | 2021 | 1521 | 0.090 |
Why?
|
Albumins | 1 | 2012 | 575 | 0.080 |
Why?
|
Oligonucleotides, Antisense | 1 | 2012 | 461 | 0.080 |
Why?
|
Receptors, Estrogen | 1 | 2018 | 2208 | 0.080 |
Why?
|
Immunoglobulins | 1 | 2013 | 853 | 0.080 |
Why?
|
Germany | 2 | 2009 | 875 | 0.080 |
Why?
|
Lymphocyte Count | 2 | 2018 | 778 | 0.080 |
Why?
|
Neutropenia | 1 | 2014 | 885 | 0.080 |
Why?
|
Patient Selection | 2 | 2018 | 4244 | 0.080 |
Why?
|
Drug Interactions | 1 | 2013 | 1416 | 0.080 |
Why?
|
Viral Proteins | 1 | 2016 | 1804 | 0.080 |
Why?
|
Coculture Techniques | 1 | 2013 | 1341 | 0.080 |
Why?
|
Cyclin D1 | 1 | 2010 | 451 | 0.080 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 2 | 2005 | 7 | 0.080 |
Why?
|
Niacinamide | 1 | 2010 | 413 | 0.080 |
Why?
|
Ki-67 Antigen | 1 | 2010 | 629 | 0.080 |
Why?
|
Antigens | 1 | 2014 | 1443 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2012 | 2265 | 0.080 |
Why?
|
Thrombophlebitis | 1 | 1989 | 289 | 0.080 |
Why?
|
Time Factors | 4 | 2021 | 39967 | 0.080 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2005 | 96 | 0.080 |
Why?
|
Jurkat Cells | 2 | 2020 | 740 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2020 | 2223 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1420 | 0.070 |
Why?
|
Suicide | 2 | 1997 | 1601 | 0.070 |
Why?
|
Flow Cytometry | 3 | 2017 | 5869 | 0.070 |
Why?
|
Cell Movement | 1 | 2020 | 5203 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2009 | 12148 | 0.070 |
Why?
|
Nitriles | 1 | 2013 | 971 | 0.070 |
Why?
|
Diagnostic Techniques, Endocrine | 1 | 2007 | 43 | 0.070 |
Why?
|
Phenylurea Compounds | 1 | 2010 | 529 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2013 | 1784 | 0.070 |
Why?
|
Mice, Inbred BALB C | 2 | 2007 | 6216 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2557 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1901 | 0.070 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2007 | 364 | 0.070 |
Why?
|
Inflammation | 3 | 2023 | 10773 | 0.070 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 4111 | 0.070 |
Why?
|
Immunohistochemistry | 4 | 2017 | 11076 | 0.070 |
Why?
|
International Agencies | 1 | 2007 | 243 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 14666 | 0.070 |
Why?
|
Vitamin D | 1 | 2020 | 3303 | 0.070 |
Why?
|
Immunoelectrophoresis, Two-Dimensional | 1 | 1985 | 2 | 0.070 |
Why?
|
Immunoelectrophoresis | 1 | 1985 | 94 | 0.070 |
Why?
|
Blood Protein Electrophoresis | 1 | 1985 | 66 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2022 | 6132 | 0.070 |
Why?
|
Electronic Health Records | 2 | 2020 | 4811 | 0.060 |
Why?
|
Adolescent | 8 | 2019 | 88319 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7407 | 0.060 |
Why?
|
Myelin-Associated Glycoprotein | 1 | 2005 | 107 | 0.060 |
Why?
|
Health Expenditures | 1 | 2018 | 2366 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2020 | 2422 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7390 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2020 | 0.060 |
Why?
|
Palliative Care | 2 | 2017 | 3598 | 0.060 |
Why?
|
Hepatic Encephalopathy | 2 | 1997 | 144 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10552 | 0.060 |
Why?
|
Paclitaxel | 1 | 2012 | 1732 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3242 | 0.060 |
Why?
|
Genital Neoplasms, Female | 1 | 2010 | 532 | 0.060 |
Why?
|
Interleukin-5 | 1 | 2005 | 269 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2017 | 3639 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7529 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8654 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 609 | 0.060 |
Why?
|
Antigenic Variation | 1 | 2004 | 118 | 0.060 |
Why?
|
Receptors, Interleukin-2 | 1 | 2005 | 562 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2009 | 771 | 0.060 |
Why?
|
Hypothyroidism | 2 | 2020 | 668 | 0.060 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 1924 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3201 | 0.060 |
Why?
|
Prospective Studies | 7 | 2024 | 54425 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 793 | 0.060 |
Why?
|
Glioblastoma | 1 | 2018 | 3482 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2018 | 857 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2018 | 18965 | 0.050 |
Why?
|
Denmark | 3 | 1997 | 771 | 0.050 |
Why?
|
Analgesics | 1 | 1990 | 1070 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2009 | 15500 | 0.050 |
Why?
|
Adoptive Transfer | 1 | 2005 | 819 | 0.050 |
Why?
|
American Heart Association | 1 | 2007 | 1039 | 0.050 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2021 | 732 | 0.050 |
Why?
|
Spleen | 2 | 2005 | 2295 | 0.050 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 712 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5368 | 0.050 |
Why?
|
Antigens, CD | 1 | 2013 | 4003 | 0.050 |
Why?
|
Opioid-Related Disorders | 1 | 1997 | 2164 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2019 | 2426 | 0.050 |
Why?
|
Chemical Fractionation | 1 | 2021 | 61 | 0.050 |
Why?
|
Rectal Neoplasms | 1 | 2010 | 1157 | 0.050 |
Why?
|
World Health Organization | 1 | 2007 | 1322 | 0.050 |
Why?
|
Body Mass Index | 1 | 2019 | 12953 | 0.050 |
Why?
|
Vancomycin | 1 | 2024 | 503 | 0.050 |
Why?
|
Mice, Inbred NOD | 1 | 2005 | 1827 | 0.050 |
Why?
|
Risk Factors | 4 | 2018 | 74206 | 0.050 |
Why?
|
Recurrence | 1 | 2013 | 8465 | 0.050 |
Why?
|
B-Lymphocytes | 2 | 2020 | 4758 | 0.050 |
Why?
|
Cholagogues and Choleretics | 1 | 2020 | 39 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 1997 | 3808 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4320 | 0.040 |
Why?
|
Lymph Nodes | 1 | 2012 | 3466 | 0.040 |
Why?
|
Warfarin | 1 | 1989 | 1483 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2020 | 4278 | 0.040 |
Why?
|
Mice, SCID | 1 | 2005 | 2626 | 0.040 |
Why?
|
Tacrolimus | 1 | 2024 | 733 | 0.040 |
Why?
|
Interferon Inducers | 1 | 2019 | 25 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2018 | 22169 | 0.040 |
Why?
|
Immunoassay | 1 | 2003 | 745 | 0.040 |
Why?
|
Eye Enucleation | 1 | 2020 | 128 | 0.040 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2005 | 822 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4740 | 0.040 |
Why?
|
Cross-Priming | 1 | 2019 | 76 | 0.040 |
Why?
|
Radiochemistry | 1 | 2019 | 49 | 0.040 |
Why?
|
Clone Cells | 1 | 2023 | 1659 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2004 | 756 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 2 | 2004 | 1802 | 0.040 |
Why?
|
Prodrugs | 1 | 2021 | 261 | 0.040 |
Why?
|
Double-Blind Method | 3 | 2020 | 12341 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2009 | 2024 | 0.040 |
Why?
|
Adsorption | 1 | 2019 | 197 | 0.040 |
Why?
|
Ecosystem | 1 | 2023 | 490 | 0.040 |
Why?
|
Prednisone | 1 | 2024 | 1563 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2020 | 523 | 0.040 |
Why?
|
Gelsolin | 1 | 1999 | 189 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 416 | 0.040 |
Why?
|
Taxoids | 1 | 2021 | 668 | 0.040 |
Why?
|
Graft Rejection | 2 | 2023 | 4445 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2004 | 1078 | 0.040 |
Why?
|
Up-Regulation | 1 | 2007 | 4124 | 0.040 |
Why?
|
ROC Curve | 2 | 2012 | 3579 | 0.040 |
Why?
|
DNA Modification Methylases | 1 | 2018 | 210 | 0.040 |
Why?
|
Endocrine Glands | 1 | 2018 | 102 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2226 | 0.040 |
Why?
|
Amines | 1 | 2019 | 281 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2021 | 983 | 0.040 |
Why?
|
Trauma Severity Indices | 1 | 1999 | 478 | 0.040 |
Why?
|
Automation | 1 | 2020 | 586 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2020 | 603 | 0.040 |
Why?
|
Granzymes | 1 | 2018 | 277 | 0.040 |
Why?
|
Aspirin | 1 | 2009 | 3133 | 0.040 |
Why?
|
Thyrotoxicosis | 1 | 2017 | 85 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2018 | 250 | 0.030 |
Why?
|
Cell Line | 2 | 2021 | 15601 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2018 | 346 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17904 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2024 | 1844 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
HLA Antigens | 1 | 2022 | 1328 | 0.030 |
Why?
|
Neutrophils | 2 | 2020 | 3767 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2016 | 6534 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2005 | 2416 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 330 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2018 | 11118 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.030 |
Why?
|
Nausea | 1 | 2018 | 679 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 422 | 0.030 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2014 | 17 | 0.030 |
Why?
|
Placebos | 1 | 2019 | 1667 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2016 | 681 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1188 | 0.030 |
Why?
|
Dermatitis | 1 | 2017 | 202 | 0.030 |
Why?
|
Thyroiditis | 1 | 2015 | 86 | 0.030 |
Why?
|
Oximes | 1 | 2016 | 303 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 1997 | 387 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2021 | 1271 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9539 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 823 | 0.030 |
Why?
|
Kidney | 2 | 2023 | 7048 | 0.030 |
Why?
|
Incidence | 1 | 2013 | 21353 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2020 | 962 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2016 | 479 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 678 | 0.030 |
Why?
|
Therapies, Investigational | 1 | 2014 | 111 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2015 | 641 | 0.030 |
Why?
|
Hepatitis C | 1 | 2004 | 1584 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 281 | 0.030 |
Why?
|
Lymphatic Diseases | 1 | 2015 | 320 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2016 | 695 | 0.030 |
Why?
|
Poisoning | 1 | 1995 | 252 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2016 | 335 | 0.030 |
Why?
|
Triage | 1 | 2020 | 986 | 0.030 |
Why?
|
Hepatitis | 1 | 2015 | 228 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2005 | 14414 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 2018 | 4174 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 9420 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2219 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3492 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1870 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2612 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 17635 | 0.030 |
Why?
|
Brachytherapy | 1 | 2020 | 1223 | 0.030 |
Why?
|
Genetic Markers | 1 | 2018 | 2601 | 0.030 |
Why?
|
Registries | 2 | 2018 | 8224 | 0.020 |
Why?
|
Survival | 1 | 2012 | 161 | 0.020 |
Why?
|
Dexamethasone | 1 | 2018 | 1948 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 803 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1809 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21012 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4544 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 1967 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10445 | 0.020 |
Why?
|
Antibody Formation | 1 | 2015 | 1395 | 0.020 |
Why?
|
Prostate | 1 | 2018 | 1770 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1667 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2449 | 0.020 |
Why?
|
Salicylates | 1 | 1990 | 127 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 517 | 0.020 |
Why?
|
ras Proteins | 1 | 2014 | 1054 | 0.020 |
Why?
|
Nonprescription Drugs | 1 | 1990 | 118 | 0.020 |
Why?
|
United States | 4 | 2019 | 72334 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2016 | 1961 | 0.020 |
Why?
|
Hypertension | 1 | 2009 | 8540 | 0.020 |
Why?
|
Prothrombin Time | 1 | 1989 | 117 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2016 | 1181 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2018 | 2803 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 1999 | 15266 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4174 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 1989 | 369 | 0.020 |
Why?
|
Narcotics | 1 | 1990 | 336 | 0.020 |
Why?
|
Pancreatitis | 1 | 2015 | 1096 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1886 | 0.020 |
Why?
|
Universities | 1 | 2013 | 993 | 0.020 |
Why?
|
Area Under Curve | 1 | 2012 | 1638 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2759 | 0.020 |
Why?
|
Point Mutation | 1 | 2013 | 1595 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 1997 | 1670 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2005 | 11528 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2018 | 5789 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1640 | 0.020 |
Why?
|
Anemia | 1 | 2016 | 1509 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6310 | 0.020 |
Why?
|
Drug Discovery | 1 | 2014 | 1051 | 0.020 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 916 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2016 | 2161 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2016 | 1797 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2015 | 2010 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 1999 | 2491 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2004 | 22176 | 0.020 |
Why?
|
Collodion | 1 | 1985 | 34 | 0.020 |
Why?
|
Odds Ratio | 1 | 2018 | 9646 | 0.020 |
Why?
|
Absorption | 1 | 2005 | 242 | 0.020 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1985 | 207 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8830 | 0.020 |
Why?
|
Reference Standards | 1 | 1989 | 1003 | 0.020 |
Why?
|
Administration, Oral | 1 | 2013 | 4021 | 0.020 |
Why?
|
Myelin Proteins | 1 | 2005 | 209 | 0.020 |
Why?
|
Cell Cycle | 1 | 2013 | 2932 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2014 | 2571 | 0.010 |
Why?
|
DNA Methylation | 1 | 2018 | 4398 | 0.010 |
Why?
|
Random Allocation | 1 | 1989 | 2395 | 0.010 |
Why?
|
Erythrocyte Membrane | 1 | 1985 | 439 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14605 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5247 | 0.010 |
Why?
|
Databases, Factual | 1 | 2019 | 7967 | 0.010 |
Why?
|
Drug Utilization | 1 | 1990 | 1188 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2915 | 0.010 |
Why?
|
Tetanus Toxin | 1 | 2003 | 46 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2009 | 1334 | 0.010 |
Why?
|
Antigen-Antibody Complex | 1 | 1985 | 510 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10508 | 0.010 |
Why?
|
Chaperonin 60 | 1 | 2003 | 97 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4425 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11903 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2005 | 584 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10209 | 0.010 |
Why?
|
Immunochemistry | 1 | 1999 | 116 | 0.010 |
Why?
|
Regression Analysis | 1 | 1989 | 6343 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6485 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12059 | 0.010 |
Why?
|
Glycoproteins | 1 | 2005 | 2203 | 0.010 |
Why?
|
Mental Disorders | 1 | 1997 | 6845 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 26125 | 0.010 |
Why?
|
Pseudotumor Cerebri | 1 | 1997 | 108 | 0.010 |
Why?
|
Injury Severity Score | 1 | 1999 | 1045 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2005 | 3208 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 23995 | 0.010 |
Why?
|
Algorithms | 1 | 2014 | 14031 | 0.010 |
Why?
|
Rabbits | 1 | 1999 | 4772 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2003 | 20098 | 0.010 |
Why?
|
Reference Values | 1 | 1999 | 4920 | 0.010 |
Why?
|
Prevalence | 1 | 2007 | 15732 | 0.010 |
Why?
|
Hospitalization | 1 | 1990 | 10723 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36426 | 0.000 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 9000 | 0.000 |
Why?
|
Respiratory Insufficiency | 1 | 1997 | 1230 | 0.000 |
Why?
|
Liver Transplantation | 1 | 1995 | 2330 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 1997 | 15842 | 0.000 |
Why?
|
Heart Failure | 1 | 1997 | 11669 | 0.000 |
Why?
|
Child | 1 | 1997 | 80153 | 0.000 |
Why?
|